Sanofi completes closing for potential vaccine against extraintestinal pathogenic E.coli
Paris: Sanofi has announced the completion of closing for its collaborative agreement with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company to develop and commercialize the vaccine candidate for extraintestinal pathogenic E. coli (9-valent) (ExPEC9V).
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis, causing approximately 10 million cases of invasive ExPEC disease annually, worldwide. It is associated with increased hospitalizations, mortality and antimicrobial resistance resulting in significant healthcare and societal costs.
Thomas Triomphe, Executive Vice President, Vaccines, Sanofi said, “At Sanofi, we believe in the power of partnership to deliver true innovation. In this case, we’re bringing together Janssen’s robust science and Sanofi’s worldwide manufacturing footprint and expertise in launching innovative vaccines. We look forward to delivering this potential first-in-class vaccine designed to help older adults around the world live longer, healthier lives.”
ExPEC9V is currently being assessed via the Phase 3 E.mbrace trial which continues to enroll patients.
Read also: Sanofi considers listing consumer unit late next year
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.